NCT05071703View on ClinicalTrials.gov

Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

April 10, 2022

Study Completion Date

November 30, 2022

Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
DRUG

Trilaciclib

"* Carboplatin combined with Etoposide (ES-SCLC patients)~* plus Topotecan (second/third line ES-SCLC patients)"

Trial Locations (1)

100021

Hainan General Hospital, Haikou

Sponsors

Collaborators (1)

G1 Therapeutics, Inc.
All Listed Sponsors
collaborator

G1 Therapeutics, Inc.

INDUSTRY

lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY